Open AccessRituximab and Therapeutic Plasma Exchange in Recurrent Focal Segmental Glomerulosclerosis Postkidney Transplantation
Author(s) -
Sami Alasfar,
Dany Matar,
Robert A. Montgomery,
Niraj M. Desai,
Bonnie E. Lonze,
Vikas Vujjini,
Michelle M. Estrella,
John Manllo Dieck,
Gebran Khneizer,
Sanja Sever,
Jochen Reiser,
Nada Alachkar
Publication year - 2018
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002008
Subject(s) - medicine , rituximab , focal segmental glomerulosclerosis , transplantation , kidney transplantation , panel reactive antibody , surgery , nephrology , kidney , proteinuria , lymphoma
Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage renal disease with a high rate of recurrence after kidney transplantation. Several factors, such as white race, rapid progression, and previous allograft failure due to recurrence, were found to be risks of recurrence. Data are limited on the benefits of rituximab and/or therapeutic plasma exchange (TPE) in preventing recurrence. In this study, we sought to assess the efficacy of rituximab and TPE for the prevention and treatment of recurrent FSGS after kidney transplantation.